CR20240453A - Derivados de oxazepina - Google Patents

Derivados de oxazepina

Info

Publication number
CR20240453A
CR20240453A CR20240453A CR20240453A CR20240453A CR 20240453 A CR20240453 A CR 20240453A CR 20240453 A CR20240453 A CR 20240453A CR 20240453 A CR20240453 A CR 20240453A CR 20240453 A CR20240453 A CR 20240453A
Authority
CR
Costa Rica
Prior art keywords
oxazepine derivatives
oxazepine
derivatives
compound
superior
Prior art date
Application number
CR20240453A
Other languages
English (en)
Inventor
Hiroyuki Mutoh
Kazuhisa Okada
Kosuke Sasaki
Kumi Kimura
Shiori Furuya
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CR20240453A publication Critical patent/CR20240453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los nuevos compuestos se proporcionan con una excelente actividad agonista del receptor de orexina tipo 2. Los compuestos están representados por la Fórmula (I) o sales farmacéuticamente aceptables de los mismos. [Fórmula 1]
CR20240453A 2022-04-22 2023-04-21 Derivados de oxazepina CR20240453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022070484 2022-04-22
PCT/JP2023/015990 WO2023204308A1 (ja) 2022-04-22 2023-04-21 オキサゼピン誘導体

Publications (1)

Publication Number Publication Date
CR20240453A true CR20240453A (es) 2025-01-29

Family

ID=88420002

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240453A CR20240453A (es) 2022-04-22 2023-04-21 Derivados de oxazepina

Country Status (19)

Country Link
US (1) US20260116891A1 (es)
EP (1) EP4512811A4 (es)
JP (2) JP7792964B2 (es)
KR (1) KR20250005359A (es)
CN (1) CN119677753A (es)
AR (1) AR129117A1 (es)
AU (1) AU2023256034A1 (es)
CA (1) CA3249764A1 (es)
CL (1) CL2024003187A1 (es)
CO (1) CO2024014096A2 (es)
CR (1) CR20240453A (es)
CU (1) CU20240034A7 (es)
DO (1) DOP2024000213A (es)
IL (1) IL316468A (es)
MX (1) MX2024012965A (es)
PE (1) PE20251873A1 (es)
TW (1) TW202409046A (es)
WO (1) WO2023204308A1 (es)
ZA (1) ZA202407953B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535890A (zh) * 2023-10-20 2025-09-16 日商帝人製藥股份有限公司 氧氮呯衍生物之結晶或其溶劑合物之結晶
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007004960A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease
TW200804364A (en) * 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
WO2012061019A2 (en) * 2010-10-25 2012-05-10 Merck Sharp & Dohme Corp. Tricyclic mglur5 receptor modulators
UY34171A (es) * 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
CA3154321A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists

Also Published As

Publication number Publication date
CA3249764A1 (en) 2025-06-17
CO2024014096A2 (es) 2025-01-13
CU20240034A7 (es) 2025-06-11
ZA202407953B (en) 2025-05-28
IL316468A (en) 2024-12-01
US20260116891A1 (en) 2026-04-30
AU2023256034A1 (en) 2024-11-07
CL2024003187A1 (es) 2025-06-23
DOP2024000213A (es) 2024-12-30
TW202409046A (zh) 2024-03-01
CN119677753A (zh) 2025-03-21
MX2024012965A (es) 2024-11-08
PE20251873A1 (es) 2025-07-22
JP2025134774A (ja) 2025-09-17
EP4512811A4 (en) 2026-01-07
JPWO2023204308A1 (es) 2023-10-26
EP4512811A1 (en) 2025-02-26
JP7792964B2 (ja) 2025-12-26
AR129117A1 (es) 2024-07-17
WO2023204308A1 (ja) 2023-10-26
KR20250005359A (ko) 2025-01-09

Similar Documents

Publication Publication Date Title
CR20240453A (es) Derivados de oxazepina
MX2022016388A (es) Compuestos de piperidina sustituida y su uso.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
ZA202400395B (en) Novel aryl ether substituted heterocyclic compound as glp1r agonist
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
AR117694A1 (es) COMPUESTO AGONISTA DEL RECEPTOR THRb Y PREPARACIÓN Y USO DEL MISMO
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
ATE372768T1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
CY1109662T1 (el) Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης
CY1108539T1 (el) Ανταγωνιστες υποδοχεα ταχυκινινης
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
MX2025004831A (es) Compuesto heterociclico
CO6190619A2 (es) Derivados de 2- quinolinona y 2-quinoxalinona y su uso como agentes antibacterianos
WO2023199091A8 (en) Heterocyclic compound
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
MX2023007429A (es) Uso como agonista selectivo de receptor de melanocortina-4.
CR20240173A (es) Compuestos de cd73
CY1124032T1 (el) Παραγωγα 3-μεθυλο-πυρρολιδινο-2,5-διονης χρησιμα ως ανταγωνιστες του υποδοχεα cgrp
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
BRPI0410315A (pt) 2-imidazo-benzotiazóis como ligandos de receptor de adenosina
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
ATE448220T1 (de) Heterocyclische modulatoren für den gaba-alpha- subtyp-selektiven rezeptor